期刊文献+

16种17-羟孕酮制备物基于两种评价方案的互通性研究 被引量:6

Commutability assessment of 16 processed materials for 17-hydroxyprogesterone based on two approaches in China
原文传递
导出
摘要 目的应用两种互通性评价方案评价16种17-羟孕酮制备物的互通性。方法互通性研究,收集2018年2月至2019年6月之间北京医院检验科的新鲜人血清共52份。根据美国临床和实验室间标准化研究所文件(CLSI)EP14-A3和国际临床化学和检验医学联合会(IFCC)互通性评价工作组报告,以血清17-羟孕酮同位素稀释液相色谱串联质谱法(ID-LC/MS/MS)为比对方法,3种临床常规分析系统(1种放射免疫法,2种LC/MS分析法)为待评方法,一同测定52个人血清样本和16种制备物的17-羟孕酮浓度,评价制备物质的互通性。结果综合两种互通性评价结果,所有正确度验证材料和国家甾体激素标准物质在LC/MS分析系统中都显示出良好的互通性,6/9的EQA材料在三种常规分析系统中都显示出互通性。其中所有材料在偏倚差值法中所有材料的LC/MS分析系统中都显示出良好的互通性。结论两种互通性评价结果有所差异,使用新鲜冰冻人血清作为血清17-羟孕酮的质评材料均能满足互通性要求。 Objective The aim of this study is to evaluate the commutability of 16 processed materials for 17-hydroxyprogesterone by using 2 commutability assessment approaches.Methods 52 serum specimens were collected in Clinical Laboratory Department of Beijing Hospital from February 2018 to June 2019.According to the report of the Clinical and Laboratory Standards Institute(EP14-A3)document and the recommendations of the International Federation of Clinical Chemistry and Laboratory Medicine(IFCC)working group on commutabilityassessment,serum 17-hydroxyprogesterone isotope diluent chromatogram tandem mass spectrometry(ID-LC/MS/MS)was used for comparison.Three clinical routine analysis systems(1 radioimmunoassay,2 LC/MS analysis methods)were used to determine the concentration of 17-hydroxyprogesterone in 52 human serum samples and 16 processed materialsfor commutabilityassessment.Results Combined with the results of the two commutability assessment,all accuracy verification materials and national steroid hormone standards showed good commutability in the LC/MS analysis system,and 6/9 EQA materials showed commutability in the three routine analysis systems.All materials showed good commutability in the LC/MS analysis system of bias difference method.Conclusions The two kinds of commutability assessment results are different.Bias difference method has more clinical value,but it has certain application limitations.The use of fresh frozen human serum as a quality assessment materialfor serum 17-hydroxyprogesterone is meets the commutability requirement.
作者 龙琪琛 张天娇 闫颖 周伟燕 李新 李水军 赵海建 陈文祥 张传宝 Long Qichen;Zhang Tianjiao;Yan Ying;Zhou Weiyan;Li Xin;Li Shuijun;Zhao Haijian;Chen Wenxiang;Zhang Chuanbao(Peking Union Medical College,National Center for Clinical Laboratories,Beijing Hospital,National Center of Gerontology,Beijing Engineering Research Center of Laboratory Medicine,Beijing 100730,China;National Center for Clinical Laboratories,Beijing Hospital,National Center of Gerontology,Beijing Engineering Research Center of Laboratory Medicine,Beijing 100730,China;Nuclear Medicine Department,Beijing Hospital,National Center of Gerontology,Beijing 100730,China;Central Laboratory,Shanghai Xuhui Central Hospital,Shanghai 200031,China)
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2020年第1期44-50,共7页 Chinese Journal of Laboratory Medicine
基金 国家重点研发计划专项项目课题(2018YFC1002204)。
关键词 17-α-羟孕酮 质量控制 色谱法 串联质谱法 17-α-Hydroxyprogesterone Quality control Chromatography,liquid Ttandem mass spectrometry
  • 相关文献

参考文献4

二级参考文献93

  • 1Gidlof S, Wedell A, Gnthenberg C, et al. Nationwide neonatal screening for congenital adrenal hyperplasia in sweden a 26-year longitudinal prospective population-based study [ J ]. JAMA Pediatr, 2014, 168 ( 6 ): 567-574. DOI: 10. 1001! jamapediatrics. 2013. 5321.
  • 2叶军.先天性肾上腺皮质增生症[M]//曾畿生,王德芬.现代儿科内分泌学.上海:上海科学技术文献出版社,2001:231-251.
  • 3White PC. Optimizing newborn screening for congenital adrenal hyperplasia[ J ]. J Pediatr, 2013,163 ( 1 ) : 10-12. DOI: 10. 1016/j. jpeds. 2013.02. 008.
  • 4Sharma R, Seth A. Congenital adrenal hyperplasia: issues in diagnosis and treatment in children[J]. Indian J Pediatr, 2014, 81 (2) :178-185. DOI: 10. 1007/s12098-013-1280-8.
  • 5Merke DP, Bomstein SR. Congenital adrenal hyperplasia [J]. Lancet,2005, 365 (9477) : 2125-2136.
  • 6Chan CL, McFann K, Taylor L, et al. Congenital adrenal hyperplasia and the second newborn screen[ J]. J Pediatr,2013, 163 ( 1 ) : 109-113. DOI : 10.1016/j. jpeds. 2013.01. 002.
  • 7Sarafoglou K, Banks K, Gaviglio A, et al. Comparison of one-tier and two-tier newborn screening metrics for congenital adrenal hyperplasia [ J ]. Pediatrics ,2012,130 ( 5 ) : e1261 - el 268. DOI : 10. 1542/peds. 2012-1219.
  • 8Speiser PW, Azziz R, Baskin LS, et al. Congenital adrenal hyperplasia due to steroid 21 -hydroxylase deficiency : an Endocrine Society clinical practice guideline [ J ]. J Clin Endocrnnl Metab,2010,95 (9) : 4133-4160. DOI: 10. 1210/jc. 2009 -2631.
  • 9Migeon C J, Wisniewski AB [ R/OL 1. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency, a guide for patients and their families [ 2006-01-25 ]. https ://www. hopkinsehildrens. org/eah/printable, html.
  • 10Auchus R J, Witchel SF, Leight KR, et al. Guidelines for the development of comprehensive care centers for congenital adrenal hyperplasia: Guidance from the CARES foundation initiative[ J ]. Int J Pediatr Endocmol, 2010, 2010:275213. DOI: 10. 1155/ 2010/275213.

共引文献111

同被引文献19

引证文献6

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部